NO3105103T3 - - Google Patents

Info

Publication number
NO3105103T3
NO3105103T3 NO15712554A NO15712554A NO3105103T3 NO 3105103 T3 NO3105103 T3 NO 3105103T3 NO 15712554 A NO15712554 A NO 15712554A NO 15712554 A NO15712554 A NO 15712554A NO 3105103 T3 NO3105103 T3 NO 3105103T3
Authority
NO
Norway
Application number
NO15712554A
Other languages
Norwegian (no)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51982773&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO3105103(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of NO3105103T3 publication Critical patent/NO3105103T3/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • A61K31/4161,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • A61K31/41621,2-Diazoles condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4738Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12Antidiarrhoeals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/06Peri-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04Ortho-condensed systems
    • C07D491/044Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/052Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO15712554A 2013-11-05 2015-03-17 NO3105103T3 (lt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361900013P 2013-11-05 2013-11-05

Publications (1)

Publication Number Publication Date
NO3105103T3 true NO3105103T3 (lt) 2018-05-12

Family

ID=51982773

Family Applications (1)

Application Number Title Priority Date Filing Date
NO15712554A NO3105103T3 (lt) 2013-11-05 2015-03-17

Country Status (42)

Country Link
US (5) US9682939B2 (lt)
EP (1) EP3065738B1 (lt)
JP (1) JP6424231B2 (lt)
KR (1) KR102350357B1 (lt)
CN (1) CN105682656B (lt)
AP (1) AP2016009165A0 (lt)
AR (1) AR098316A1 (lt)
AU (1) AU2014346919B2 (lt)
BR (1) BR112016009630B1 (lt)
CA (1) CA2927705C (lt)
CL (1) CL2016000982A1 (lt)
CR (1) CR20160212A (lt)
CU (1) CU24375B1 (lt)
CY (1) CY1120273T1 (lt)
DK (1) DK3065738T3 (lt)
EA (1) EA030430B1 (lt)
ES (1) ES2670984T3 (lt)
GT (1) GT201600085A (lt)
HR (1) HRP20180817T1 (lt)
HU (1) HUE039155T2 (lt)
IL (1) IL245242B (lt)
JO (1) JO3454B1 (lt)
LT (1) LT3065738T (lt)
MA (1) MA39088B1 (lt)
MX (1) MX364834B (lt)
MY (1) MY175903A (lt)
NO (1) NO3105103T3 (lt)
NZ (1) NZ719078A (lt)
PE (1) PE20160682A1 (lt)
PH (1) PH12016500777A1 (lt)
PL (1) PL3065738T3 (lt)
PT (1) PT3065738T (lt)
RS (1) RS57179B1 (lt)
SG (1) SG11201603026PA (lt)
SI (1) SI3065738T1 (lt)
SV (1) SV2016005192A (lt)
TN (1) TN2016000143A1 (lt)
TR (1) TR201807321T4 (lt)
TW (1) TWI662027B (lt)
UY (1) UY35818A (lt)
WO (1) WO2015069666A1 (lt)
ZA (1) ZA201602555B (lt)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2545964A1 (en) 2011-07-13 2013-01-16 Phenex Pharmaceuticals AG Novel FXR (NR1H4) binding and activity modulating compounds
MX364834B (es) 2013-11-05 2019-05-08 Novartis Ag Composiciones y metodos para modular los receptores x farnesoides.
TWI698430B (zh) 2015-02-13 2020-07-11 南北兄弟藥業投資有限公司 三環化合物及其在藥物中的應用
CN107531721B (zh) * 2015-04-30 2020-07-17 诺华股份有限公司 用于调节法尼醇x受体的稠合的三环吡唑衍生物
KR20180115270A (ko) 2016-02-22 2018-10-22 노파르티스 아게 Fxr 효능제를 사용하는 방법
CA2968836A1 (en) 2016-06-13 2017-12-13 Gilead Sciences, Inc. Fxr (nr1h4) modulating compounds
SI3730487T1 (sl) 2016-06-13 2022-08-31 Gilead Sciences, Inc. Azetidinski derivati kot modulatorji FXR (NR1H4)
CA3036757A1 (en) * 2016-09-14 2018-03-22 Novartis Ag Novel regimes of fxr agonists
JOP20190040A1 (ar) * 2016-09-14 2019-03-10 Novartis Ag توليفة من ناهضات fxr
CN109789119A (zh) * 2016-10-05 2019-05-21 诺华股份有限公司 用于治疗或预防纤维化、硬化疾病或障碍的含fxr激动剂的复合组合物
CN107973790A (zh) * 2016-10-22 2018-05-01 合帕吉恩治疗公司 杂环fxr调节剂
WO2018183193A1 (en) 2017-03-28 2018-10-04 Gilead Sciences, Inc. Therapeutic combinations for treating liver diseases
CA3066217A1 (en) * 2017-06-05 2018-12-13 National University Of Singapore Compounds useful in inhibiting human trefoil factor 3
EP3668843A1 (en) 2017-08-15 2020-06-24 Inflazome Limited Sulfonylureas and sulfonylthioureas as nlrp3 inhibitors
WO2019034692A1 (en) 2017-08-15 2019-02-21 Inflazome Limited SULFONYLURATES AND SULFONYLTHIOURES AS INHIBITORS OF NLRP3
UY37847A (es) 2017-08-15 2019-03-29 Inflazome Ltd Sulfonilureas y sulfoniltioureas útiles como inhibidores de nlrp3
JP2020533339A (ja) * 2017-09-13 2020-11-19 ノバルティス アーゲー Fxrアゴニストを含む組合せ
MX2020004423A (es) 2017-11-09 2020-08-06 Inflazome Ltd Nuevos compuestos de sulfonamida carboxamida.
CN110128432B (zh) * 2018-02-02 2021-03-02 广东东阳光药业有限公司 含氮三环化合物及其在药物中的应用
EP3759077A1 (en) 2018-03-02 2021-01-06 Inflazome Limited Novel compounds
JOP20210017A1 (ar) 2018-07-25 2021-01-21 Novartis Ag مثبطات جسيم التهابي nlrp3
EA202191566A1 (ru) 2019-01-15 2021-11-01 Джилид Сайенсиз, Инк. Соединения, модулирующие fxr (nr1h4)
US10610280B1 (en) 2019-02-02 2020-04-07 Ayad K. M. Agha Surgical method and apparatus for destruction and removal of intraperitoneal, visceral, and subcutaneous fat
JP2022519906A (ja) 2019-02-19 2022-03-25 ギリアード サイエンシーズ, インコーポレイテッド Fxrアゴニストの固体形態
AR119731A1 (es) 2019-05-17 2022-01-05 Novartis Ag Inhibidores del inflamasoma nlrp3
CA3139291A1 (en) 2019-07-18 2021-01-21 Jacky Vonderscher Method for decreasing adverse-effects of interferon
TW202122078A (zh) 2019-09-06 2021-06-16 瑞士商諾華公司 使用lta4h抑制劑治療肝臟疾病之方法
US20230060715A1 (en) 2020-01-15 2023-03-02 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of fxr agonists for treating an infection by hepatitis d virus
CN113387828A (zh) * 2020-03-14 2021-09-14 江巨东 一种阿利克仑中间体的制备方法
WO2022037663A1 (zh) * 2020-08-21 2022-02-24 苏州晶云药物科技股份有限公司 苯甲酸衍生物的新晶型及其制备方法
JP2024502673A (ja) 2021-01-14 2024-01-22 ウエヌイグレックオ・ファーマ Hbv感染の処置のためのfxrアゴニストとifnの相乗効果
JP2024517181A (ja) 2021-04-28 2024-04-19 ウエヌイグレックオ・ファーマ 組合せ治療としてfxrアゴニストを使用するtlr3アゴニストの効果の強い増強
US20240067627A1 (en) 2022-08-03 2024-02-29 Novartis Ag Nlrp3 inflammasome inhibitors
WO2024044778A2 (en) * 2022-08-26 2024-02-29 Celmatix Inc. Novel modulators of fshr and uses thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050143449A1 (en) * 2002-11-15 2005-06-30 The Salk Institute For Biological Studies Non-steroidal farnesoid X receptor modulators and methods for the use thereof
BRPI0712262A2 (pt) * 2006-05-24 2012-07-10 Lilly Co Eli agonistas de fxr
WO2008033534A2 (en) * 2006-09-15 2008-03-20 Thales Avionics, Inc. System and method for wirelessly transferring content to and from an aircraft
TW200906823A (en) * 2007-07-16 2009-02-16 Lilly Co Eli Compounds and methods for modulating FXR
CU24152B1 (es) * 2010-12-20 2016-02-29 Irm Llc 1,2 oxazol-8-azabiciclo[3,2,1]octano 8 il como moduladores de fxr
MX364834B (es) 2013-11-05 2019-05-08 Novartis Ag Composiciones y metodos para modular los receptores x farnesoides.
CN107531721B (zh) 2015-04-30 2020-07-17 诺华股份有限公司 用于调节法尼醇x受体的稠合的三环吡唑衍生物

Also Published As

Publication number Publication date
DK3065738T3 (en) 2018-06-06
JO3454B1 (ar) 2020-07-05
TW201612163A (en) 2016-04-01
UY35818A (es) 2015-05-29
MX2016005865A (es) 2016-07-13
US20160340317A1 (en) 2016-11-24
JP2016535784A (ja) 2016-11-17
CN105682656B (zh) 2019-11-05
US10077240B2 (en) 2018-09-18
SI3065738T1 (en) 2018-06-29
PL3065738T3 (pl) 2018-07-31
PH12016500777B1 (en) 2016-05-30
AU2014346919B2 (en) 2017-02-02
ES2670984T3 (es) 2018-06-04
BR112016009630A8 (pt) 2020-04-07
EP3065738A1 (en) 2016-09-14
RS57179B1 (sr) 2018-07-31
NZ719078A (en) 2018-07-27
PT3065738T (pt) 2018-06-04
SG11201603026PA (en) 2016-05-30
MY175903A (en) 2020-07-15
HUE039155T2 (hu) 2018-12-28
CY1120273T1 (el) 2019-07-10
CR20160212A (es) 2016-07-22
PH12016500777A1 (en) 2016-05-30
MA39088A1 (fr) 2017-07-31
EA201690930A1 (ru) 2016-08-31
US20170275256A1 (en) 2017-09-28
PE20160682A1 (es) 2016-07-23
BR112016009630B1 (pt) 2021-02-09
JP6424231B2 (ja) 2018-11-14
US20210253534A1 (en) 2021-08-19
AP2016009165A0 (en) 2016-04-30
US9682939B2 (en) 2017-06-20
US11021446B2 (en) 2021-06-01
KR102350357B1 (ko) 2022-01-14
KR20160079091A (ko) 2016-07-05
WO2015069666A1 (en) 2015-05-14
HRP20180817T1 (hr) 2018-06-29
MX364834B (es) 2019-05-08
IL245242B (en) 2019-03-31
EA030430B1 (ru) 2018-08-31
IL245242A0 (en) 2016-06-30
LT3065738T (lt) 2018-05-10
AU2014346919A1 (en) 2016-05-12
US20200247757A1 (en) 2020-08-06
AR098316A1 (es) 2016-05-26
CL2016000982A1 (es) 2016-10-07
SV2016005192A (es) 2016-11-21
US10683271B2 (en) 2020-06-16
MA39088B1 (fr) 2018-06-29
CA2927705A1 (en) 2015-05-14
TWI662027B (zh) 2019-06-11
EP3065738B1 (en) 2018-02-28
TN2016000143A1 (en) 2017-10-06
US20190062283A1 (en) 2019-02-28
TR201807321T4 (tr) 2018-06-21
CU24375B1 (es) 2018-12-05
CU20160063A7 (es) 2016-09-30
CA2927705C (en) 2021-09-21
ZA201602555B (en) 2017-06-28
GT201600085A (es) 2019-07-19
CN105682656A (zh) 2016-06-15

Similar Documents

Publication Publication Date Title
NO3105103T3 (lt)
AP2016009275A0 (lt)
BR102016010778A2 (lt)
BR112015007533A2 (lt)
BR112016008313A2 (lt)
BR112014017733A2 (lt)
BR112014017739A2 (lt)
BR112014018480A2 (lt)
BR112014017855A2 (lt)
BR112014017765A2 (lt)
BR112016013531A2 (lt)
BR112014021878A2 (lt)
BR112014017669A2 (lt)
BR112016011988A2 (lt)
BR112014018468A2 (lt)
BR112014017901A2 (lt)
BR112014018207A2 (lt)
BR112015015948A2 (lt)
BR112014017722A2 (lt)
BR112014018578A2 (lt)
BR112014018483A2 (lt)
BR112014017653A2 (lt)
BR112014017794A2 (lt)
BR112016014051A2 (lt)
BR112016004691A2 (lt)